Business Wire

Kyoto Semiconductor Announces Two UV Sensors for Deep UV Sensing Applications

7.2.2023 04:30:00 EET | Business Wire | Press release

Share

Kyoto Semiconductor Co., Ltd. (President and CEO Yoshihisa Shinya, Head office: Fushimi-ku, Kyoto city), a leading optical device solution manufacturer with world-class technologies and Japanese quality, has announced two products of GaN*1 UV sensor; "KPDU086SU27-H11Q and KPDU086SU31-H11Q".

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230204005014/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Kyoto Semiconductor KPDU086SU27/KPDU086SU31 (Photo: Business Wire)

The UV sensors "KPDU086SU27-H11Q" and "KPDU086SU31-H11Q" were developed with the aim of achieving higher sensitivity than conventional Si*2 type UV sensors to meet the needs of the deep UV*3 sensing market.

Since conventional Si-type UV sensors detect a wide range of wavelengths, it is common to apply a filter to limit the sensitivity to the UV wavelength range. The amount of light was attenuated by passing through the filter.

The newly developed KPDU086SU27-H11Q and KPDU086SU31-H11Q use GaN to enable direct light reception at the light receiving part of the sensor without using a filter as GaN has sensitivity to a specific wavelength range of ultraviolet light. It is now possible to obtain approximately three times as high sensitivity as Si-type UV sensors. *4

In addition, the products have sensitivity in the wavelength range limited to UV-B*5 and UV-C*6, which are in high demand among ultraviolet rays.

The new products can be used to monitor the ultraviolet light intensity of germicidal lamps in food factories, medical institutions, and water purification-related institutions, and to monitor the light intensity of ozone detection light sources.

The mass production of the GaN UV sensors "KPDU086SU27-H11Q and KPDU086SU31-H11Q" are scheduled to start on April 28, 2023.

For more information
https://www.kyosemi.co.jp/en/products/kpdu086su27-h11q/
https://www.kyosemi.co.jp/en/products/kpdu086su31-h11q/

*1 GaN: Gallium nitride a type of semiconductor
*2 Si: Silicon, a type of semiconductor
*3 Deep ultraviolet rays: UV rays in the emission wavelength range of λ = 200-300 nm. UV-B and UV-C are said to be deep UV rays.
*4 Comparison between KPDU086SU27-H11Q and our Si UV sensor KPDU400F-2
https://www.kyosemi.co.jp/products/kpdu400f-2/
*5 UV-B: Ultraviolet rays in the emission wavelength range of λ = 280 to 315 nm. Sensitivity wavelength range of KPDU086SU31-H11Q
*6 UV-C: Ultraviolet rays in the emission wavelength range of λ = 100 to 280 nm. Sensitivity wavelength range of KPDU086SU27-H11Q

About Kyoto Semiconductor

Kyoto Semiconductor was established in 1980 in Kyoto as a dedicated manufacturer of optical semiconductors. The semiconductors manufactured offer superlative performance and precision, suited for use in optical transmission. They are manufactured end-to-end, including pre- and post-processing, and together with Kyoto Semiconductor’s unique packaging technology, at our location in Japan and made available to customers around the world. Kyoto Semiconductor leads the industry with world-standard technologies for optical device solutions based on Japanese quality and attention to production detail.

Company Website: https://www.kyosemi.co.jp/

*Product names, company names, and organization names mentioned in this press release are trademarks or registered trademarks of their respective companies.
*All contents of this press release are as of the date of publication and subject to change without notice.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations, Kyoto Semiconductor Co., Ltd.
Email: Media_relation@kyosemi.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye